Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | TPMT | P51580 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | GALK1 | P51570 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10339486 | 0.87 | KDM4E (0.49) | HSD17B10ALDH1A1KDM4EHPGDNPSR1 | |
| SCHEMBL4113785 | 0.82 | HSD17B10 (0.71) | HSD17B10TPMTTSHRAPOBEC3AHTT | |
| SCHEMBL5240714 | 0.82 | HSD17B10 (0.51) | HSD17B10TPMTTSHRAPOBEC3AHTT | |
| SCHEMBL30745030 | 0.82 | HSD17B10 (0.51) | HSD17B10TPMTTSHRAPOBEC3AHTT | |
| SCHEMBL8640946 | 0.81 | TPMT (0.50) | HSD17B10TPMTTSHRAPOBEC3AHTT | |
| SCHEMBL4879449 | 0.81 | KDM4E (0.44) | HSD17B10ALDH1A1KDM4EHPGDNPSR1 | |
| SCHEMBL3709174 | 0.80 | HSD17B10 (0.49) | HSD17B10TPMTTSHRAPOBEC3AHTT | |
| SCHEMBL3349066 | 0.80 | TPMT (0.59) | HSD17B10TPMTTSHRAPOBEC3AHTT | |
| SCHEMBL12419331 | 0.79 | GALK1 (0.59) | TPMTHTTALDH1A1KDM4EHPGD | |
| SCHEMBL20944322 | 0.79 | HSD17B10 (0.49) | HSD17B10TPMTTSHRAPOBEC3AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220315-A1 | Alkenyldiarylmethane non-nucleoside HIV-1 reverse transcriptase inhibitors | CUSHMAN MARK S (US) | 2003-11-27 | — | — | US | disclosed |
| EP-1047656-A4 | ALKENYLDIARYLMETHANE NON-NUCLEOSIDE HIV-1 REVERSE TRANSCRIPTASE INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2003-07-30 | — | — | EP | disclosed |
| US-6569897-B1 | Such as 3',3\"-dibromo-4',4\"-dimethyoxy-5',5\"-bis(methyoxy carbonyl)-1,1-diphenylethene | PURDUE RESEARCH FOUNDATION | 2003-05-27 | — | — | US | disclosed |
| EP-1047656-A1 | ALKENYLDIARYLMETHANE NON-NUCLEOSIDE HIV-1 REVERSE TRANSCRIPTASE INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999036384-A1 | ALKENYLDIARYLMETHANE NON-NUCLEOSIDE HIV-1 REVERSE TRANSCRIPTASE INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 1999-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220315-A1 | Alkenyldiarylmethane non-nucleoside HIV-1 reverse transcriptase inhibitors | SAMHD1, DNTT, ADAM8 | HSD17B10 227/4885TPMT 194/4885TSHR 4336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.